Trials / Unknown
UnknownNCT02989779
Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour
NK1 Antagonists for Pathological Aggression: A Protocol for Harmful, Impulsive, and Self-/Aggressive Behavior (AHIMSA-1) Trial
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- St. Joseph's Healthcare Hamilton · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Neurokinin (NK) -1 antagonist will be administered to study patients in a double-blind placebo trial. Patients receive assessments including Anger Disorder Scale (ADS) and Modified Overt Aggression Scale (MOAS) and perform computerized study tasks during MRI before the trial begins. Patients receive either one week of the drug or one week of placebo and perform the same tasks and assessments. Then patients receive another week of the alternate pill, followed by another round of tasks during MRI and assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NK1 Antagonist | |
| DRUG | Placebo Oral Capsule |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-03-01
- Completion
- 2020-06-01
- First posted
- 2016-12-12
- Last updated
- 2019-04-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02989779. Inclusion in this directory is not an endorsement.